» Articles » PMID: 23261783

Matrix Metalloproteinase-28 Deletion Exacerbates Cardiac Dysfunction and Rupture After Myocardial Infarction in Mice by Inhibiting M2 Macrophage Activation

Overview
Journal Circ Res
Date 2012 Dec 25
PMID 23261783
Citations 132
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: Matrix metalloproteinase (MMP)-28 regulates the inflammatory and extracellular matrix responses in cardiac aging, but the roles of MMP-28 after myocardial infarction (MI) have not been explored.

Objective: To determine the impact of MMP-28 deletion on post-MI remodeling of the left ventricle (LV).

Methods And Results: Adult C57BL/6J wild-type (n=76) and MMP null (MMP-28((-/-)), n=86) mice of both sexes were subjected to permanent coronary artery ligation to create MI. MMP-28 expression decreased post-MI, and its cell source shifted from myocytes to macrophages. MMP-28 deletion increased day 7 mortality because of increased cardiac rupture post-MI. MMP-28(-/-) mice exhibited larger LV volumes, worse LV dysfunction, a worse LV remodeling index, and increased lung edema. Plasma MMP-9 levels were unchanged in the MMP-28((-/-)) mice but increased in wild-type mice at day 7 post-MI. The mRNA levels of inflammatory and extracellular matrix proteins were attenuated in the infarct regions of MMP-28(-/-) mice, indicating reduced inflammatory and extracellular matrix responses. M2 macrophage activation was impaired when MMP-28 was absent. MMP-28 deletion also led to decreased collagen deposition and fewer myofibroblasts. Collagen cross-linking was impaired as a result of decreased expression and activation of lysyl oxidase in the infarcts of MMP-28(-/-) mice. The LV tensile strength at day 3 post-MI, however, was similar between the 2 genotypes.

Conclusions: MMP-28 deletion aggravated MI-induced LV dysfunction and rupture as a result of defective inflammatory response and scar formation by suppressing M2 macrophage activation.

Citing Articles

The interplay of senescence and MMPs in myocardial infarction: implications for cardiac aging and therapeutics.

Balaraman A, Altamimi A, Babu M, Goyal K, Padmapriya G, Bansal P Biogerontology. 2025; 26(1):46.

PMID: 39832057 DOI: 10.1007/s10522-025-10190-6.


IL-4-Induced Gene 1: A Potential Player in Myocardial Infarction.

Shen R, Ding Y, Dong Q, Wang Y, Yu J, Pan C Rev Cardiovasc Med. 2024; 25(9):337.

PMID: 39355609 PMC: 11440439. DOI: 10.31083/j.rcm2509337.


Macrophage heterogeneity in myocardial infarction: Evolution and implications for diverse therapeutic approaches.

Kanuri B, Sreejit G, Biswas P, Murphy A, Nagareddy P iScience. 2024; 27(7):110274.

PMID: 39040061 PMC: 11261154. DOI: 10.1016/j.isci.2024.110274.


Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets.

Chen R, Zhang H, Tang B, Luo Y, Yang Y, Zhong X Signal Transduct Target Ther. 2024; 9(1):130.

PMID: 38816371 PMC: 11139930. DOI: 10.1038/s41392-024-01840-1.


Early Injury Landscape in Vein Harvest by Single-Cell and Spatial Transcriptomics.

Michaud M, Mota L, Bakhtiari M, Thomas B, Tomeo J, Pilcher W Circ Res. 2024; 135(1):110-134.

PMID: 38808504 PMC: 11189745. DOI: 10.1161/CIRCRESAHA.123.323939.


References
1.
Thielmann M, Dorge H, Martin C, Belosjorow S, Schwanke U, van de Sand A . Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine. Circ Res. 2002; 90(7):807-13. DOI: 10.1161/01.res.0000014451.75415.36. View

2.
Matsui Y, Ikesue M, Danzaki K, Morimoto J, Sato M, Tanaka S . Syndecan-4 prevents cardiac rupture and dysfunction after myocardial infarction. Circ Res. 2011; 108(11):1328-39. DOI: 10.1161/CIRCRESAHA.110.235689. View

3.
Rouillard A, Holmes J . Mechanical regulation of fibroblast migration and collagen remodelling in healing myocardial infarcts. J Physiol. 2012; 590(18):4585-602. PMC: 3477759. DOI: 10.1113/jphysiol.2012.229484. View

4.
Houser S, Margulies K, Murphy A, Spinale F, Francis G, Prabhu S . Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res. 2012; 111(1):131-50. DOI: 10.1161/RES.0b013e3182582523. View

5.
Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T . Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol. 2003; 285(3):H1229-35. DOI: 10.1152/ajpheart.00207.2003. View